FR3052071B1 - Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide - Google Patents

Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide Download PDF

Info

Publication number
FR3052071B1
FR3052071B1 FR1655221A FR1655221A FR3052071B1 FR 3052071 B1 FR3052071 B1 FR 3052071B1 FR 1655221 A FR1655221 A FR 1655221A FR 1655221 A FR1655221 A FR 1655221A FR 3052071 B1 FR3052071 B1 FR 3052071B1
Authority
FR
France
Prior art keywords
polyaminoacid
glucagon
compositions
injectable solution
aqueous injectable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1655221A
Other languages
English (en)
Other versions
FR3052071A1 (fr
Inventor
Alexandre GEISSLER
Segolene Laage
Richard Charvet
Olivier Soula
David Duracher
Gregory Meiffren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1655221A priority Critical patent/FR3052071B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to JP2018564397A priority patent/JP2019517560A/ja
Priority to KR1020197000540A priority patent/KR20190025905A/ko
Priority to US15/616,627 priority patent/US10485851B2/en
Priority to CA3026802A priority patent/CA3026802A1/fr
Priority to SG11201810939PA priority patent/SG11201810939PA/en
Priority to BR112018075259-2A priority patent/BR112018075259A2/pt
Priority to CN201780047755.9A priority patent/CN109562063A/zh
Priority to CN201780049290.0A priority patent/CN109562064A/zh
Priority to EP17728542.6A priority patent/EP3463295B1/fr
Priority to MX2018015069A priority patent/MX2018015069A/es
Priority to PCT/EP2017/063888 priority patent/WO2017211918A1/fr
Priority to PCT/EP2017/063887 priority patent/WO2017211917A1/fr
Priority to CA3027238A priority patent/CA3027238A1/fr
Priority to EP17728541.8A priority patent/EP3463294B1/fr
Priority to BR112018075250-9A priority patent/BR112018075250A2/pt
Priority to AU2017277589A priority patent/AU2017277589A1/en
Priority to KR1020197000533A priority patent/KR20190026748A/ko
Priority to SG11201810901VA priority patent/SG11201810901VA/en
Priority to AU2017277590A priority patent/AU2017277590A1/en
Priority to JP2018564218A priority patent/JP2019521107A/ja
Priority to US15/616,542 priority patent/US10383918B2/en
Priority to MX2018015070A priority patent/MX2018015070A/es
Publication of FR3052071A1 publication Critical patent/FR3052071A1/fr
Publication of FR3052071B1 publication Critical patent/FR3052071B1/fr
Application granted granted Critical
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
FR1655221A 2016-06-07 2016-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide Expired - Fee Related FR3052071B1 (fr)

Priority Applications (23)

Application Number Priority Date Filing Date Title
FR1655221A FR3052071B1 (fr) 2016-06-07 2016-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide
JP2018564218A JP2019521107A (ja) 2016-06-07 2017-06-07 ヒトグルカゴン及び統計上のコポリアミノ酸を含む注射用溶液の形態の組成物
CA3027238A CA3027238A1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
CA3026802A CA3026802A1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique
SG11201810939PA SG11201810939PA (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
BR112018075259-2A BR112018075259A2 (pt) 2016-06-07 2017-06-07 composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0
CN201780047755.9A CN109562063A (zh) 2016-06-07 2017-06-07 包含人胰高血糖素和末端接枝的共聚氨基酸的可注射水溶液形式的组合物
CN201780049290.0A CN109562064A (zh) 2016-06-07 2017-06-07 包含人胰高血糖素和统计共聚氨基酸的可注射水溶液形式的组合物
EP17728542.6A EP3463295B1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacidegreffe en bout de chaine
MX2018015069A MX2018015069A (es) 2016-06-07 2017-06-07 Composiciones bajo la forma de solución acuosa inyectable que comprende glucagón humano y co-poliaminoacido estadístico.
PCT/EP2017/063888 WO2017211918A1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacidegreffe en bout de chaine
PCT/EP2017/063887 WO2017211917A1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique
JP2018564397A JP2019517560A (ja) 2016-06-07 2017-06-07 ヒトグルカゴン及びコポリアミノ酸を含む注射用溶液の形態の組成物
US15/616,627 US10485851B2 (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
MX2018015070A MX2018015070A (es) 2016-06-07 2017-06-07 Composiciones en forma de solucion acuosa inyectable, que comprende glucagon humano y un co-poliaminoacido injertado en el extremo.
AU2017277589A AU2017277589A1 (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
KR1020197000533A KR20190026748A (ko) 2016-06-07 2017-06-07 인간 글루카곤 및 말단-그래프트된 코폴리아미노산을 포함하는 주사가능한 수용액 형태의 조성물
SG11201810901VA SG11201810901VA (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
AU2017277590A AU2017277590A1 (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
KR1020197000540A KR20190025905A (ko) 2016-06-07 2017-06-07 인간 글루카곤 및 통계적 코폴리아미노산을 포함하는 주사가능한 수용액 형태의 조성물
US15/616,542 US10383918B2 (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid
BR112018075250-9A BR112018075250A2 (pt) 2016-06-07 2017-06-07 composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0
EP17728541.8A EP3463294B1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1655221A FR3052071B1 (fr) 2016-06-07 2016-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide
FR1655221 2016-06-07

Publications (2)

Publication Number Publication Date
FR3052071A1 FR3052071A1 (fr) 2017-12-08
FR3052071B1 true FR3052071B1 (fr) 2018-09-07

Family

ID=56990534

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1655221A Expired - Fee Related FR3052071B1 (fr) 2016-06-07 2016-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide

Country Status (1)

Country Link
FR (1) FR3052071B1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019086559A1 (fr) * 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3079414B1 (fr) * 2018-03-27 2020-05-01 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3072875B1 (fr) * 2017-10-31 2020-11-06 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EP3731858A1 (fr) 2017-12-07 2020-11-04 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
SG11202005322RA (en) 2017-12-07 2020-07-29 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
BR112020011486A2 (pt) 2017-12-07 2020-11-17 Adocia Solução injetável de ph 7 compreendendo pelo menos uma insulina basal comum pi de 5,8 a 8,5 e um copoliaminoácido contendo cargas de carboxilato e radicais hidrofóbicos
AU2018380993A1 (en) 2017-12-07 2020-06-11 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) * 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
CN104114155B (zh) * 2012-01-09 2019-02-15 阿道恰公司 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液

Also Published As

Publication number Publication date
FR3052071A1 (fr) 2017-12-08

Similar Documents

Publication Publication Date Title
FR3052071B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide
MA51018A (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
MA42950A (fr) Administration d'agents de potentialisation de cftr modifiés au deutérium
DK3497094T3 (da) Tlr7/8-antagonister og anvendelser deraf
MA51287A (fr) Analogues d'incrétine et leurs utilisations
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
MA49678A (fr) Compositions sous forme d'une solution aqueuse injectable comprenant au moins l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA46996A (fr) Conjugués comprenant un agoniste double de glp-1/glucagon, un lieur et de l'acide hyaluronique
DK3532029T3 (da) Flydende farmaceutisk sammensætning
MA49116A (fr) Compositions pharmaceutiques contenant de l'insuline
IL248785B (en) Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents
MA51017A (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
ZA202001988B (en) Liquid personal cleansing composition
ZA201906728B (en) Liquid personal cleansing composition
MA51600A (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MA43042A (fr) Composition aqueuse d'apomorphine pour une administration sous-cutanée
MA42480A (fr) Préparations pharmaceutiques de dabigatran sous forme de base libre
FR3039096B1 (fr) Pneumatique comprenant des elements de renfort sous forme de bandelettes partiellement superposees
MA44850A (fr) Composition ophtalmique comprenant une combinaison synergique de glycogène et d'acide hyaluronique ou d'un sel de celui-ci
FR3021555B1 (fr) Catalyseur sous la forme d'un barillet avec une geometrie definissant un trou
IT201600130706A1 (it) 4 amino-2-pirido-biciclo pirimidine e lo uso come medicamenti
IT201600122310A1 (it) Composizione per uso nella terapia di alterazioni dell'intestino
MA54509A (fr) Composition émolliente sous forme d'émulsion
FR3021536B1 (fr) Composition photoprotectrice fluide sous forme d'emulsion huile-dans-eau

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Search report ready

Effective date: 20171208

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

ST Notification of lapse

Effective date: 20210206